Dr. Kulreet Chaudhary Partners with Healthy Directions Neurologist and Ayurvedic practitioner, Dr. Kulreet Chaudhary has developed Prajna Ayurveda herbals with...
OV329 Phase 1 trial is progressing on trackAn IV formulation candidate suitable for future clinical trials has been achieved for...
-The TGFβ1 and TGFβ3 isoforms are predictive --Validation of TGFβ2 as therapeutic target AGOURA HILLS, Calif., March 13, 2023 (GLOBE...
-- Full results from ELPIS I trial published in European Heart Journal Open – -- First patient to be randomized...
Illustration 1: Effect of anti-CHI3L1 on Primary Lung Cancer Illustration 2: Effect of bi-specific antibody on Glioblastoma tumorsProvidence, RI, March...
Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks...
Topline Data Expected in 2Q 2023SEATTLE, Wash. and VANCOUVER, British Columbia, March 08, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences,...
OV350 is the first reported compound that directly binds to and activates the KCC2 co-transporter, a target implicated in neuronal...
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on developing novel...
GUILFORD, Conn., March 06, 2023 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking medical device company that created the...
MINNEAPOLIS, March 06, 2023 (GLOBE NEWSWIRE) -- Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic...
AJ201 is being evaluated in a Phase 1b/2a clinical trial in the U.S. for the rare X-linked genetic neurodegenerative disease...
VANCOUVER, British Columbia, March 02, 2023 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) (the “Company” or...
Swoop® Portable MR Imaging® system positioned to offer even greater clinical utility in neurocritical careGUILFORD, Conn., Feb. 28, 2023 (GLOBE...
- Rare disease company in preclinical development for congenital hyperinsulinism - - Acquisition is strong strategic fit...
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated...
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher diseaseBETHESDA, Md., Feb. 27, 2023 (GLOBE...
CAMBRIDGE, Mass. and NEW YORK, NY, Feb. 27, 2023 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage...
Recommendation based on a Phase 3 trial demonstrating superior survival outcomes for Libtayo plus chemotherapy compared to chemotherapy aloneTARRYTOWN, N.Y.,...
Additional interim biomarker and efficacy data from first six patients continue to demonstrate both the high and low dose of...